Support teaching, research, and patient care.
University Hospital of the West Indies
Traumatic brain injury with a focus on epidemiology and outcomes.
A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .
The purpose of this study is to investigate the safety and effectiveness of a medication
called CellCept in treating refractory (has not responded to other treatments) interstitial
CellCept belongs to a class of medications called immuno-suppressants. Immuno-suppressants
work in the body by reducing the immune system's ability to produce certain reactions that
can cause inflammation. In some people, the inflammation produced by their immune system can
damage healthy tissues and cause symptoms of pain and discomfort. CellCept is approved by the
U.S. Food and Drug Administration (FDA) for use in patients who have had an organ transplant.
When used in combination with other drugs, CellCept helps to prevent the rejection of the
transplanted organ and is used widely in patients who have received kidney, liver and heart
transplants. CellCept is also frequently used but not FDA approved for the treatment of
severe rheumatoid arthritis which is a disease caused when the body's immune system acts
against healthy tissues in the joints.
Due to its special activity, CellCept may be useful in treating certain inflammatory diseases
or conditions like interstitial cystitis.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
View full details